| |
PHQ9 score
|
GAD7 score
|
|---|
|
GAD7 score
|
0.7, p<0.0001
|
1.00
|
|
SLEDAI score
|
0.07, p=0.6
|
0.2, p=0.2
|
|
Steroid dose
|
-0.05, p=0.7
|
-0.1, p=0.3
|
|
Disease duration
|
0.06, p=0.6
|
0.02, p=0.9
|
|
PROMIS measures:
|
|
Worse depression
|
0.7, p<0.0001
|
0.7, p<0.0001
|
|
Worse anxiety
|
0.6, p<0.0001
|
0.8, p<0.0001
|
|
Worse fatigue
|
0.7, p<0.0001
|
0.6, p<0.0001
|
|
Stronger peer relationships
|
-0.3, p=0.002
|
-0.4, p=0.009
|
|
Lower physical functioning
|
0.4, p=0.0001
|
0.4, p=0.0004
|
|
Higher pain interference
|
0.5, p<0.0001
|
0.6, p<0.0001
|
|
Higher pain severity
|
0.5, p<0.0001
|
0.4, p=0.0003
|
- PHQ9 (Patient Health Questionnaire-9) scores ranged from 0-27; GAD7 (Generalized Anxiety 7-Index) scores ranged from 0-21. SLEDAI (SLE Disease Activity Index 2K Modification) scores ranged from 0-20 (of a possible range 0-105). Steroid dose was current daily dose. PROMIS (Patient Reported Outcome Measurement Information System) scores were measured as T-scores, except for pain severity measured on a scale of 1-10. Spearman rho correlation coefficients shown
